使用尿肌酐校正来强化CYFRA 21-1作为潜在子宫内膜异位症生物标志物的作用。
Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker .
作者信息
Saputra Nicko Pisceski Kusika, Samsulhadi Samsulhadi, Hendarto Hendy, Sa'adi Ashon, Pudjirahardjo Widodo J, Arsana I Wayan, Yanuari Relly, Dwiningsih Sri Ratna
机构信息
Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Riau, Pekanbaru, Riau, Indonesia.
出版信息
F1000Res. 2025 May 14;13:46. doi: 10.12688/f1000research.135167.2. eCollection 2024.
BACKGROUND
This study aimed to determine the accuracy of CYFRA 21-1 using urine creatinine correction (CYFRA/Cr) as a biomarker of endometriosis.
METHODS
This study includes 73 patients from the Indonesian population, with 38 endometriosis and 35 non-endometriosis patients based on laparoscopy. Urine detection of CYFRA 21-1 was done by ELISA method and corrected by urine creatinine constant factor (CYFRA/Cr). Urine creatinine us detected using the ECLIA method.
RESULTS
The CYFRA/Cr ratio was identified in the proliferative and secretory phases. CYFRA 21-1 and CYFRA/Cr levels were significantly higher in endometriosis and were higher in the proliferative phase compared to the secretory phase. The best accuracy was obtained in CYFRA which was corrected with urine creatinine in the proliferative phase with a sensitivity value, specificity, and cutoff value of 94.7%, 94.4%, and of 3,547.99 ng/gr, respectively, compared to CYFRA 21-1 urine levels without correction of creatinine.
CONCLUSIONS
The CYFRA to creatinine urine ratio detected in the proliferative phase showed the optimum sensitivity and specificity compared to CYFRA 21-1 spot urine. It has the potential to be a biomarker of endometriosis.
背景
本研究旨在确定使用尿肌酐校正的细胞角蛋白19片段（CYFRA 21-1）（CYFRA/Cr）作为子宫内膜异位症生物标志物的准确性。
方法
本研究纳入了73名印度尼西亚患者，其中38例为子宫内膜异位症患者，35例为非子宫内膜异位症患者，均经腹腔镜检查确诊。采用酶联免疫吸附测定（ELISA）法检测尿CYFRA 21-1，并通过尿肌酐常数因子进行校正（CYFRA/Cr）。采用电化学发光免疫分析（ECLIA）法检测尿肌酐。
结果
在增殖期和分泌期均检测到CYFRA/Cr比值。子宫内膜异位症患者的CYFRA 21-1和CYFRA/Cr水平显著高于非子宫内膜异位症患者，且增殖期高于分泌期。与未校正肌酐的CYFRA 21-1尿水平相比，增殖期用尿肌酐校正的CYFRA的准确性最佳，其灵敏度值、特异性和临界值分别为94.7%、94.4%和3547.99 ng/gr。
结论
与CYFRA 21-1即时尿相比，增殖期检测到的CYFRA与尿肌酐比值显示出最佳的灵敏度和特异性。它有可能成为子宫内膜异位症的生物标志物。
Zotero 插件